These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7116642)

  • 1. Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.
    Grenier A; Lescault A; Laberge C; Gagné R; Mamer O
    Clin Chim Acta; 1982 Aug; 123(1-2):93-9. PubMed ID: 7116642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone.
    Sassa S; Kappas A
    J Clin Invest; 1983 Mar; 71(3):625-34. PubMed ID: 6826727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of delta-aminolevulinate synthase in liver.
    Sassa S; Kappas A
    Trans Assoc Am Physicians; 1982; 95():42-52. PubMed ID: 7182986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the enzymic defects in hereditary tyrosinemia.
    Lindblad B; Lindstedt S; Steen G
    Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4641-5. PubMed ID: 270706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Succinylacetone and delta-aminolevulinic acid dehydratase in hereditary tyrosinemia: immunochemical study of the enzyme.
    Sassa S; Fujita H; Kappas A
    Pediatrics; 1990 Jul; 86(1):84-6. PubMed ID: 2359685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of 4,6-dioxoheptanoic acid (succinylacetone), 3,5-dioxooctanedioic acid (succinylacetoacetate) and 4-Oxo-6-hydroxyheptanoic acid in the urine from patients with hereditary tyrosinemia.
    Lindblad B; Steen G
    Biomed Mass Spectrom; 1982 Oct; 9(10):419-24. PubMed ID: 7171740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.
    Manabe S; Sassa S; Kappas A
    J Exp Med; 1985 Sep; 162(3):1060-74. PubMed ID: 3928801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable isotope dilution analysis of succinylacetone using electron capture negative ion mass fragmentography: an accurate approach to the pre- and neonatal diagnosis of hereditary tyrosinemia type I.
    Jakobs C; Dorland L; Wikkerink B; Kok RM; de Jong AP; Wadman SK
    Clin Chim Acta; 1988 Feb; 171(2-3):223-31. PubMed ID: 3286060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrophotometric microassay for delta-aminolevulinate dehydratase in dried-blood spots as confirmation for hereditary tyrosinemia type I.
    Schulze A; Frommhold D; Hoffmann GF; Mayatepek E
    Clin Chem; 2001 Aug; 47(8):1424-9. PubMed ID: 11468232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
    Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
    Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["Succinylacetone effect' after oral homogentisate loading].
    Laberge C; Lescault A; Grenier A; Gagné R
    Union Med Can; 1981 Jul; 110(7):621-5. PubMed ID: 7292795
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of succinylacetone (4,6-dioxoheptanoic acid) on delta-aminolevulinate synthase activity and the content of heme in monolayers of chick embryo liver cells.
    Schoenfeld N; Greenblat Y; Epstein O; Atsmon A
    Biochim Biophys Acta; 1982 Dec; 721(4):408-17. PubMed ID: 7159602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia.
    Berger R; van Faassen H; Smith GP
    Clin Chim Acta; 1983 Oct; 134(1-2):129-41. PubMed ID: 6652907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical analysis of succinylacetone and 4-hydroxyphenyllactate in amniotic fluid using selective ion monitoring.
    Jakobs C; Sweetman L; Nyhan WL
    Prenat Diagn; 1984; 4(3):187-94. PubMed ID: 6463026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester prenatal diagnosis of tyrosinemia type I by amniotic fluid succinylacetone determination.
    Jakobs C; Stellaard F; Kvittingen EA; Henderson M; Lilford R
    Prenat Diagn; 1990 Feb; 10(2):133-4. PubMed ID: 2343022
    [No Abstract]   [Full Text] [Related]  

  • 16. Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I.
    Laberge C; Grenier A; Valet JP; Morissette J
    Am J Hum Genet; 1990 Aug; 47(2):325-8. PubMed ID: 2378358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antenatal diagnosis and aid to the management of hereditary tyrosinaemia by use of a specific and sensitive GC-MS assay for succinylacetone.
    Pettit BR; MacKenzie F; King GS; Leonard JV
    J Inherit Metab Dis; 1984; 7 Suppl 2():135-6. PubMed ID: 6434868
    [No Abstract]   [Full Text] [Related]  

  • 18. Hereditary tyrosinemia of chronic course without rickets and renal tubular dysfunction.
    Søvik O; Kvittingen EA; Steen-Johnsen J; Halvorsen S
    Acta Paediatr Scand; 1990 Nov; 79(11):1063-8. PubMed ID: 2267924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.
    Fällström SP; Lindblad B; Steen G
    Acta Paediatr Scand; 1981; 70(3):315-20. PubMed ID: 7246125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On rat renal aminolevulinate transport and metabolism in experimental Fanconi syndrome.
    Roth KS; Carter BE; Moses LC; Spencer PD
    Biochem Med Metab Biol; 1990 Dec; 44(3):238-46. PubMed ID: 2288767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.